Lupus (SLE): vizsgálatok itt: Spanyolország
43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Barcelona, Córdoba, Galdakao, Madrid, Sabadell, Santander, Seville, Valencia
- Életkor
- 18 év to 70 év
- People
- 245 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07430306 - 4. fázisTaking peopleCarotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
- Where
- Barcelona, Bilbao, Ciudad Real, Córdoba, Elche, Las Palmas De Gran Canaria, Madrid, Murcia, Orihuela, Palma, San Cristóbal de La Laguna, Santander, Sant Joan d'Alacant, Torrelavega, Vitoria, Hospital laredo
- Életkor
- 50 év and over
- People
- 1944
- Run by
- Instituto de Investigación Marqués de Valdecilla
See details and how to joinNCT07611747 · EU 2025-521086-28-00 - 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- A Coruña, Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Valladolid, Vigo
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Badalona, Barcelona, Elche, La Laguna, Madrid, Pamplona, San Sebastián de los Reyes, Santander, Santiago de Compostela, Valencia, Valladolid, Vigo, Vitoria
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 3. fázisTaking peoplePhase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- Where
- Barcelona, Pamplona, Vigo
- Életkor
- 18 év to 100 év
- People
- 348 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00 - 1. fázisTaking peopleTo Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Pamplona, Sevilla, Vitoria
- Életkor
- 18 év to 75 év
- People
- 46 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Málaga, Pamplona, Santiago de Compostela, Valencia
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Castello De La Plana, Córdoba, Madrid, Mérida, Valladolid
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Where
- Esplugues de Llobregat, Madrid, Valencia
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Sevilla, Valladolid, Zaragoza
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- A Coruña, Badajoz, Barcelona, Castello De La Plana, Las Palmas De Gran Canaria, Madrid, Málaga, Mérida, Sabadell, Santander, Santiago de Compostela, Sevilla, Vigo, Vitoria
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - No phaseTaking peopleA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Where
- Barcelona, Mérida
- Életkor
- 16 év and over
- People
- 223 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07175285 - 1. fázisTaking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Madrid, Pamplona, Santiago de Compostela
- Életkor
- 18 év to 75 év
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - 2. fázisNot yet taking people in SpanyolországA Trial of LAD603 in Patients with Systemic Lupus Erythematosus
- Where
- Barcelona, Pamplona
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- Almirall S.A.
See details and how to join2026-527200-24-00 · EU 2026-527200-24-00 - 1. fázisTaking peopleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- Barcelona, Córdoba, Madrid
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Badalona, Barcelona, Galdakao, Madrid, Vitoria
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 1. fázisTaking peopleDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- Where
- Madrid, Málaga, Pamplona, Sevilla
- Életkor
- 18 év to 60 év
- People
- 90 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00 - 3. fázisNot yet taking people in SpanyolországRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- A Coruña, Barcelona, Castello De La Plana, Granada, Las Palmas De Gran Canaria, Madrid, Valencia, Vigo. Pontevedra
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - 1. fázisTaking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Where
- Sevilla
- Életkor
- 18 év to 70 év
- People
- 24 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00 - 1. fázisTaking peopleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Where
- Córdoba, Pamplona, Seville, Valencia
- Életkor
- 18 év to 70 év
- People
- 80 worldwide
- Run by
- CRISPR Therapeutics
See details and how to joinNCT06925542 - 1/2. fázisTaking peopleA Study of RO7871996 in Participants with Systemic Lupus Erythematosus
- Where
- Barcelona, Madrid, Pamplona, Sabadell
- Életkor
- 18 év and over
- People
- 7
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2026-527221-35-00 · EU 2026-527221-35-00 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Mérida, Sevilla, Valladolid
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- A Coruña, Badajoz, Barcelona, Castello De La Plana, Madrid, Málaga, Mérida, Murcia, Sabadell, San Cristobal De La Laguna, Santander, Santiago de Compostela, Sevilla, Vigo, Vitoria
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1/2. fázisTaking peopleRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Where
- Madrid, Pamplona
- Életkor
- 12 év to 65 év
- People
- 28 worldwide
- Run by
- Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01 - 1. fázisNot yet taking people in SpanyolországA study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
- Where
- Barcelona, Vitoria
- Életkor
- Up to 64 év
- People
- 10 worldwide
- Run by
- UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00